FrancophonIA/ELRC3.0 huggingface dataset:
English: Taking into account the PRAC Assessment Report for the non-interventional imposed PASS final report for the medicinal product(s) containing the active substance Alanine, arginine, aspartic acid, cysteine, glucose, glutamic acid, glycine, histidine, isoleucine, leucine, lysine monohydrate, methionine, ornithine hydrochloride, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine, calcium chloride, magnesium acetate, potassium acetate, sodium chloride, sodium glycerophosphate, refined soybean oil, refined olive oil and concerned by the PASS final report , the scientific conclusions are as follows:
Croatian: Uzimajući u obzir PRAC-ovo izvješće o ocjeni završnog izvješća zatraženog neintervencijskog ispitivanja sigurnosti primjene lijeka nakon stavljanja u promet (engl. post-authorization safety study, PASS) za lijek(ove) koji sadrži(e) djelatne tvari: alanin, arginin, aspartatnu kiselinu, cistein, glukozu, glutamatnu kiselinu, glicin, histidin, izoleucin, leucin, lizin hidrat, metionin, ornitinklorid, fenilalanin, prolin, serin, taurin, treonin, triptofan, tirozin, valin, kalcijev klorid, magnezijev acetat, kalijev acetat, natrijev klorid, natrijev glicerofosfat, rafinirano sojino ulje i rafinirano maslinovo ulje, a koje su obuhvaćene završnim izvješćem PASS-a, znanstveni zaključci su sljedeći:
English: Changes to be made to the conditions of the marketing authorisation(s) of medicinal product(s) containing the active substance Alanine, arginine, aspartic acid, cysteine, glucose, glutamic acid, glycine, histidine, isoleucine, leucine, lysine monohydrate, methionine, ornithine hydrochloride, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine, calcium chloride, magnesium acetate, potassium acetate, sodium chloride, sodium glycerophosphate, refined soybean oil, refined olive oil concerned by the non-interventional imposed PASS final report
Croatian: Izmjene uvjeta odobrenja za stavljanje lijeka u promet za lijek(ove) koji sadrži(e) djelatne tvari: alanin, arginin, aspartatnu kiselinu, cistein, glukozu, glutamatnu kiselinu, glicin, histidin, izoleucin, leucin, lizin hidrat, metionin, ornitinklorid, fenilalanin, prolin, serin, taurin, treonin, triptofan, tirozin, valin, kalcijev klorid, magnezijev acetat, kalijev acetat, natrijev klorid, natrijev glicerofosfat, rafinirano sojino ulje i rafinirano maslinovo ulje, a koje su obuhvaćene završnim izvješćem zatraženog neintervencijskog ispitivanja sigurnosti primjene lijeka nakon stavljanja u promet
English: Annex II Conditions to the Marketing Authorisation(s)>
Croatian: Uvjeti odobrenja za stavljanje lijeka u promet
English: MA (EU) number (Invented) name Strength Pharmaceutical form Route of administration
Croatian: Broj (EU) odobrenja (Zaštićeno) ime Doza
English: Blister (PVC/PVdC/Alu) 100 x 1 capsules (unit dose)
Croatian: 100 x 1 kapsula (jedinična doza)
English: Blister (PVC/PVdC/Alu) 50 x 1 tablets
Croatian: 50 x 1 tableta (jedinična doza)
English: Make sure you do the following:
Croatian: Pobrinite se da učinite sljedeće:
English: This medicine could seriously harm your baby.
Croatian: Ovaj lijek može ozbiljno naškoditi Vašem djetetu.
English: If you are HIV positive or if your liver function is severely impaired, your doctor may recommend additional tests.
Croatian: Ako ste HIV pozitivni ili ako Vam je funkcija jetre teško oštećena, Vaš liječnik može preporučiti dodatne pretrage.
English: In the event of neutropenia:
Croatian: U slučaju neutropenije:
English: Non-clinical studies have been conducted in animal species including mice, rats, rabbits, dogs and monkeys.
Croatian: Neklinička ispitivanja provedena su na životinjskim vrstama, uključujući miševe, štakore, kuniće, pse i majmune.
English: Deferiprone Lipomed will be most effective if you do not miss any doses.
Croatian: Deferipron Lipomed će biti najučinkovitiji ako ne propustite uzeti niti jednu dozu.
English: Ask your doctor which method is best for you.
Croatian: Pitajte svojeg liječnika koja je metoda najbolja za Vas.
English: Deferiprone Lipomed can be taken with or without food; however, you may find it easier to remember to take Deferiprone Lipomed if you take it with your meals.
Croatian: Deferipron Lipomed se može uzimati s hranom ili bez nje; međutim, možda će Vam ipak biti lakše zapamtiti da uzmete Deferipron Lipomed ako ga uzimate s obrocima.
English: In most cases, the pain disappeared while patients continued taking deferiprone.
Croatian: U većini slučajeva bol je nestala dok su bolesnici nastavili uzimati deferipron.
English: Adverse reaction frequencies: Very common (≥1/10), Common (≥1/100 to <1/10), not known (cannot be estimated from the available data).
Croatian: Učestalosti nuspojava: vrlo često (≥1/10), često (≥1/100 i <1/10), nepoznato (ne može se utvrditi iz dostupnih podataka).
English: In addition he or she might ask you to undergo liver biopsies.
Croatian: Nadalje, od Vas može tražiti da se podvrgnete biopsijama jetre.
English: There are limited data available on the use of deferiprone in children between 6 and 10 years of age, and no data on deferiprone use in children under 6 years of age.
Croatian: Dostupni podatci o primjeni deferiprona u djece u dobi od 6 do 10 godina su ograničeni, a nema podataka o primjeni deferiprona u djece mlađe od 6 godina starosti.
English: Even though agranulocytosis only affects 1 to 2 out of 100 users, it is important to monitor your blood on a regular basis.
Croatian: Iako se agranulocitoza javlja kod svega 1 do 2 na 100 osoba, važno je da redovito kontrolirate svoju krvnu sliku.
English: COMMON (≥1/100 to <1/10)
Croatian: ČESTO (≥ 1/100 i < 1/10)
English: Please consult with your doctor or pharmacist before taking vitamin C with Deferiprone Lipomed.
Croatian: Molimo savjetujte se sa svojim liječnikom ili ljekarnikom prije nego uzmete vitamin C s lijekom Deferipron Lipomed.
English: Electronic mail: lipomed@lipomed.com
Croatian: E-pošta: lipomed@lipomed.com
English: Deferiprone Lipomed is packaged in blisters.
Croatian: Deferipron Lipomed je pakiran u blisterima.
English: Have your blood monitored on a weekly basis.
Croatian: Pratite krvnu sliku svakoga tjedna.
English: FREQUENCY NOT KNOWN
Croatian: UČESTALOST NEPOZNATA
English: Provide protective isolation and if clinically indicated, admit patient to the hospital.
Croatian: Osigurajte zaštitnu izolaciju bolesnika i ako je to klinički indicirano, hospitalizirajte bolesnika.
English: Not known (frequency cannot be estimated from the available data): - allergic reactions including skin rash or hives
Croatian: Nije poznato (učestalost se ne može utvrditi iz dostupnih podataka) - alergijske reakcije uključujući kožni osip i koprivnjaču
English: Deferiprone was concluded to produce no significant prolongation of the QT interval.
Croatian: Zaključeno je da deferipron ne uzrokuje značajno produljenje QT intervala.
English: ((Inside 2))
Croatian: ((Unutarnji dio 2))
English: This metabolite lacks ironbinding capability due to inactivation of the 3-hydroxy group of deferiprone.
Croatian: Ovaj metabolit nema sposobnost vezivanja željeza zbog inaktivacije 3-hidroksilne skupine deferiprona.
English: Deferiprone did not show direct mutagenic properties; however, it did display clastogenic characteristics in in vitro assays and in vivo in animals.
Croatian: Deferipron nije pokazao izravna mutagena svojstva; međutim pokazao je klastogene karakteristike u testovima in vitro i in vivo na životinjama.
English: Aluminium/PVC-PVDC blisters in cartons of 100 film-coated tablets.
Croatian: Aluminijski/PVC/PVDC blisteri u kartonskim kutijama od 100 filmom obloženih tableta.
English: The amount of Deferiprone Lipomed that you take will depend on your weight.
Croatian: Količina lijeka Deferipron Lipomed koju uzimate ovisit će o Vašoj tjelesnoj težini.
English: Studies LA16-0102, LA-01 and LA08-9701 compared the efficacy of deferiprone with that of deferoxamine in controlling serum ferritin in transfusion-dependent thalassaemia patients.
Croatian: Ispitivanja LA16-0102, LA-01 i LA08-9701 uspoređivala su djelotvornost deferiprona s deferoksaminom za kontrolu feritina u serumu u bolesnika s talasemijom ovisnom o transfuziji.
English: If you become pregnant while taking Deferiprone Lipomed, stop taking the medicine immediately and tell your doctor.
Croatian: Ako zatrudnite dok uzimate Deferipron Lipomed, odmah prestanite uzimati lijek i odmah to recite svom liječniku.
English: Neurological disorders have been observed in children treated with more than 2.5 times the maximum recommended dose for several years but have also been observed with standard doses of deferiprone.
Croatian: Neurološki poremećaji opaženi su u djece koja su liječena s više od 2,5 puta većom dozom od maksimalno preporučene doze tijekom nekoliko godina, no opaženi su i kod standardnih doza deferiprona.
English: ((Inside 1))
Croatian: ((Unutarnji dio 1))
English: • To warn women of childbearing age to not become pregnant because deferiprone may seriously harm the unborn baby
Croatian: • upozoravanje žena u reproduktivnoj dobi da ne zatrudne jer deferipron može imati ozbiljne štetne posljedice za nerođeno dijete.
English: Additional side effects in children
Croatian: Dodatne nuspojave kod djece
English: Systemic exposure to the inactive 3-Oglucuronide increased with decreasing eGFR.
Croatian: Sistemska izloženost neaktivnom 3-O-glukuronidu povećavala se sa smanjenjem eGFR-a.
English: There is a small chance that you may develop agranulocytosis (very low white blood cell count) while taking Deferiprone Lipomed, which may lead to a serious infection.
Croatian: Postoji mala šansa da ćete razviti agranulocitozu (vrlo niska razina bijelih krvnih stanica) prilikom uzimanja lijeka Deferipron Lipomed, što može dovesti do ozbiljne infekcije.
English: The Patient/Carer reminder card shall contain the following key messages (full text is included in Annex IIIA of the marketing authorisation):
Croatian: Kartica s podsjetnikom za bolesnike/njegovatelje mora sadržavati sljedeće ključne poruke (cjeloviti tekst dio je Priloga III.A odobrenja za stavljanje lijeka u promet):
English: If taken during pregnancy, Deferiprone Lipomed may seriously harm the unborn baby.
Croatian: Ako se uzima tijekom trudnoće, lijek Deferipron Lipomed može ozbiljno naškoditi nerođenom djetetu.
English: Instruct the patient to immediately discontinue deferiprone and all other medicinal products with a potential to cause neutropenia.
Croatian: Uputite bolesnika da odmah prekine uzimanje deferiprona i svih drugih lijekova koji mogu uzrokovati neutropeniju.
English: Limited information is available regarding re-challenge.
Croatian: Dostupne su ograničene informacije koji se odnose na ponovnu primjenu deferiprona.
English: Following a dose of 25 mg/kg, lower peak serum concentrations have been detected in patients in the fed state (85 µmol/l) than in the fasting state (126 µmol/l), although there was no decrease in the amount of deferiprone absorbed when it was given with food.
Croatian: Nakon doze od 25 mg/kg, niže vršne koncentracije u serumu utvrđene su u nahranjenih bolesnika (85 µmol/l) nego u onih natašte (126 µmol/l), premda nije bilo smanjenja u količini apsorbiranog deferiprona ako se davao s hranom.
English: If you experience nausea or vomiting, it may help to take your Deferiprone Lipomed with some food.
Croatian: Ako osjetite mučninu ili povraćate, od pomoći može biti uzimati Deferipron Lipomed s nešto hrane.
English: Limited data are available on the combined use of deferiprone and deferasirox, and caution should be applied when considering the use of such combination.
Croatian: Dostupni su ograničeni podatci o kombiniranoj primjeni deferiprona i deferasiroksa, i potreban je oprez ako se razmatra primjena takve kombinacije.
English: • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Croatian: • preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1.
English: Pharmacotherapeutic group: Iron chelating agents, ATC code: V03AC02
Croatian: Farmakoterapijska skupina: lijekovi za kelaciju željeza, ATK oznaka: V03AC02
English: Deferiprone Lipomed is an iron chelator, a type of medicine that removes excess iron from the body.
Croatian: Deferipron Lipomed je kelator željeza, vrsta lijeka koja uklanja višak željeza iz tijela.
English: Treatment with deferiprone should not be initiated if the patient is neutropenic.
Croatian: Liječenje deferipronom ne treba započinjati ako bolesnik ima neutropeniju.
English: • Pregnancy (see section 4.6).
Croatian: • trudnoća (vidjeti dio 4.6).
English: This rate should be considered in the context of the underlying elevated incidence of neutropenia in thalassaemia patients, particularly in those with hypersplenism.
Croatian: Ovu stopu treba promatrati u kontekstu podležeće povišene incidencije neutropenije u bolesnika s talasemijom, osobito u onih s hipersplenizmom.
English: Doses of deferiprone in those studies ranged from 50 to 100 mg/kg/day and doses of deferoxamine from 40 to 60 mg/kg/day.
Croatian: Doze deferiprona u tim ispitivanjima bile su u rasponu od 50 do 100 mg/kg/dan, a doze deferoksamina od 40 do 60 mg/kg/dan.
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Croatian: Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu .
English: If the patient develops an infection while on deferiprone, therapy should be interrupted and the neutrophil count monitored more frequently.
Croatian: Ako bolesnik razvije infekciju dok je na terapiji deferipronom, liječenje treba prekinuti i češće pratiti broj neutrofila.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/18/1310/001
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/18/1310/001
English: The active substance is deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a bidentate ligand which binds to iron in a 3:1 molar ratio.
Croatian: Djelatna tvar je deferipron (3-hidroksi-1,2-dimetilpiridin-4-on), bidentatni ligand koji se veže za željezo u molarnom omjeru 3:1.
English: In the event of severe neutropenia or agranulocytosis:
Croatian: U slučaju teške neutropenije ili agranulocitoze:
English: They recovered from these symptoms after discontinuation of deferiprone.
Croatian: Djeca su se oporavila od tih simptoma nakon prekida primjene lijeka deferiprona.
English: Lipomed GmbH Hegenheimer Strasse 2 79576 Weil am Rhein GERMANY
Croatian: Lipomed GmbH Hegenheimer Strasse 2 79576 Weil am Rhein NJEMAČKA
English: Increased liver enzymes
Croatian: Pretrage povišeni jetreni enzimi
English: Chronic overdose and neurological disorders
Croatian: Kronično predoziranje i neurološki poremećaji
English: Deferiprone therapy should be initiated and maintained by a physician experienced in the treatment of patients with thalassaemia.
Croatian: Terapiju deferipronom treba započeti i provoditi liječnik iskusan u liječenju bolesnika s talasemijom.
English: Regardless of the degree of renal impairment, the majority of the dose of deferiprone was excreted in the urine over the first 24 hours as deferiprone 3-O-glucuronide.
Croatian: Bez obzira na stupanj oštećenja bubrega, većina doze deferiprona izlučuje se putem urina tijekom prva 24 sata u obliku deferipron 3-O-glukuronida.
English: Dose adjustments when used with other iron chelators In patients for whom monotherapy is inadequate, Deferiprone Lipomed may be used with deferoxamine at the standard dose (75 mg/kg/day) but should not exceed 100 mg/kg/day.
Croatian: Prilagodbe doza kada se koristi s drugim kelatorima željeza Kod bolesnika kod kojih je monoterapija neodgovarajuća, Deferipron Lipomed može se koristiti s deferoksaminom u standardnoj dozi (75 mg/kg/dan) ali doza ne bi smjela prijeći 100 mg/kg/dan.
English: Because white blood cells help to fight infection, a low neutrophil count may place you at risk of developing a serious and potentially life-threatening infection.
Croatian: Budući da bijele krvne stanice pomažu u borbi protiv infekcije, niski broj neutrofila može staviti u rizik od razvoja ozbiljne i potencijalno po život opasne infekcije.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON
Croatian: PODATCI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA
English: Do not take medicines known to cause neutropenia or agranulocytosis (see “Do not take Deferiprone Lipomed”).
Croatian: Nemojte uzimati lijekove za koje se zna da uzrokuju neutropeniju ili agranulocitozu (pogledajte dio „Nemojte uzimati Deferipron Lipomed“).
English: Deferiprone and deferoxamine were equivalent in promoting a net stabilization or reduction of body iron load, despite the continuous transfusional iron administration in those patients (no difference in proportion of patients with a negative trend in serum ferritin between the two treatment groups by regression analysis; p>0.05).
Croatian: Deferipron i deferoksamin bili su jednaki u poboljšanju stabilizacije ili redukcije opterećenja tijela željezom unatoč kontinuiranoj primjeni željeza u transfuzijama u ovih bolesnika (nije bilo razlike u udjelu bolesnika s negativnim trendom feritina u serumu između dviju liječenih skupina dobivene regresijskom analizom; p >0,05).
English: Data from the pooled safety database from clinical trials (1343 patient-years exposure to deferiprone monotherapy and 244 patient-years exposure to deferiprone and deferoxamine) showed statistically significant (p<0.05) differences in the incidence of adverse reactions based on System Organ Class for “Cardiac disorders”, “Musculoskeletal and connective tissue disorders” and “Renal and urinary disorders”.
Croatian: Podatci iz objedinjene baze podataka o sigurnosti primjene dobivenih iz kliničkih ispitivanja (1343 bolesnik-godina izloženosti monoterapiji deferipronom i 244 bolesnik-godina izloženosti deferipronu i deferoksaminu) pokazali su statistički značajne (p<0,05) razlike u incidenciji nuspojava koje se temelje na klasifikaciji organskih sustava za „srčane poremećaje”, „poremećaje mišićnokoštanog sustava i vezivnog tkiva” te „poremećaja bubrega i mokraćnog sustava”.
English: The observed incidence of the less severe form of neutropenia (neutrophils <1.5 x 109/l) is 4.9% (2.5 cases per 100 patient-years).
Croatian: Opažena incidencija manje teškog oblika neutropenije (neutrofili <1,5 x 109/l) je 4,9% (2,5 slučajeva na 100 bolesnik-godina).
English: Deferiprone has been shown to cause neutropenia, including agranulocytosis.
Croatian: Pokazano je da deferipron uzrokuje neutropeniju, uključujući agranulocitozu.
English: One pack contains 100 film-coated tablets.
Croatian: Jedno pakiranje sadrži 100 filmom obloženih tableta.
English: Deferiprone Lipomed in combination with another chelator (see section 4.4) is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction (see section 4.2).
Croatian: Deferipron Lipomed u kombinaciji s drugim kelatorom (vidjeti dio 4.4.) indiciran je kod bolesnika s talasemijom major kada je monoterapija s bilo kojim kelatorom željeza neučinkovita ili kada prevencija ili liječenje posljedica preopterećenja željezom opasnih po život opravdava brzu ili intenzivnu korekciju (vidjeti dio 4.2).
English: Plasma Zn2+ concentration Monitoring of plasma Zn2+ concentration, and supplementation in case of a deficiency, is recommended.
Croatian: Preporučuje se praćenje koncentracije Zn2+ u plazmi i u slučaju deficita njegova nadoknada.
English: Fertility No effects on fertility or early embryonic development were noted in animals (see section 5.3).
Croatian: Plodnost Nisu primijećeni učinci na plodnost ili rani embrionalni razvoj u životinja (vidjeti dio 5.3).
English: The risk of agranulocytosis and neutropenia is higher if the baseline absolute neutrophil count (ANC) is less than 1.5 x 109/l.
Croatian: Rizik od agranulocitoze i neutropenije je viši ako su početne vrijednosti apsolutnog broja neutrofila (ABN) manje od 1,5 x 109/l.
English: The effect of Deferiprone Lipomed in decreasing the body iron is directly influenced by the dose and the degree of iron overload.
Croatian: Učinak lijeka Deferipron Lipomed na snižavanje razine željeza u tijelu izravno je ovisan o dozi i stupnju preopterećenja željezom.
English: Data from the published literature on iron balance studies in patients with thalassaemia major show that the use of deferiprone concurrently with deferoxamine (co-administration of both chelators during the same day, either simultaneously or sequentially, e.g., deferiprone during the day and deferoxamine during the night), promotes greater iron excretion than either drug alone.
Croatian: Podatci iz objavljene literature o ispitivanjima ravnoteže željeza kod bolesnika s talasemijom major pokazuju da primjena deferiprona istodobno s deferoksaminom (istodobna primjena oba kelatora istog dana, bilo simultano ili jedan iza drugog, npr. deferipron tijekom dana a deferoksamin tijekom noći) potiče veće izlučivanje željeza nego bilo koji od lijekova primijenjen samostalno.
English: If you take more Deferiprone Lipomed than you should There are no reports of acute overdose with deferiprone.
Croatian: Ako uzmete više lijeka Deferipron Lipomed nego što ste trebali Nema prijava o akutnom predoziranju deferipronom.
English: After starting Deferiprone Lipomed therapy, it is recommended that serum ferritin concentrations, or other indicators of body iron load, be monitored every two to three months to assess the long-term effectiveness of the chelation regimen in controlling the body iron load.
Croatian: Nakon započinjanja terapije lijekom Deferipron Lipomed preporučuje se praćenje koncentracija feritina u serumu, ili drugih pokazatelja opterećenja tijela željezom, svaka dva do tri mjeseca, radi procjene dugotrajne učinkovitosti režima kelacije u svrhu kontrole opterećenja tijela željezom.
English: Prescribers are reminded that the use of doses above 100 mg/kg/day is not recommended.
Croatian: Podsjećamo liječnike koji propisuju ovaj lijek da se primjena doza iznad 100 mg/kg/dan ne preporučuje.
English: In the event of agranulocytosis, re-challenge is contraindicated.
Croatian: U slučaju agranulocitoze ponovna primjena lijeka je kontraindicirana.
English: The patient's neutrophil count should be monitored every week.
Croatian: Bolesniku se mora kontrolirati broj neutrofila svaki tjedan.
English: Episodes of hypotonia, instability, inability to walk, and hypertonia with inability of limb movement have been reported in children in the post-marketing setting with standard doses of deferiprone.
Croatian: Epizode hipotonije, nestabilnosti, nemogućnosti hodanja te hipertonije s nemogućnošću pokretanja udova prijavljene su kod djece u periodu nakon stavljanja lijeka u promet sa standardnim dozama deferiprona.
English: Other medicines and Deferiprone Lipomed
Croatian: Drugi lijekovi i Deferipron Lipomed
English: Clinical studies have demonstrated that deferiprone is effective in promoting iron excretion and that a dose of 25 mg/kg three times per day can prevent the progression of iron accumulation as assessed by serum ferritin, in patients with transfusion-dependent thalassaemia.
Croatian: Klinička ispitivanja pokazala su da je deferipron učinkovit u poboljšanju izlučivanja željeza, i da u dozi od 25 mg/kg tri puta na dan može spriječiti progresiju akumulacije željeza, a što je dokazivo mjerenjem feritina u serumu, u bolesnika s talasemijom ovisnom o transfuziji.
English: Please refer to the patient/carer reminder card provided in the folding box.
Croatian: Molimo pogledajte u karticu s podsjetnikom za bolesnika/njegovatelja koja se nalazi u sklopivoj kutiji.
English: In these patients careful monitoring of liver histology is recommended.
Croatian: U ovih se bolesnika preporučuje pažljivo praćenje histoloških promjena u jetri.
English: What you need to know before you take Deferiprone Lipomed
Croatian: Što morate znati prije nego uzmete Deferipron Lipomed
English: Deferiprone Lipomed contains sodium
Croatian: Deferipron Lipomed sadrži natrij